Technology

May 7, 2015.

May 7, 2015.

May 6, 2015.

May 6, 2015.

May 6, 2015.

Alexion announces it will expand its rare disease pipeline with a definitive agreement to acquire Synageva.

Eleven of the leading US biosimilar developers have collaborated to form the Biosimilars Forum, a nonprofit organization formed to expand patient access to biosimilars.

May 5, 2015.

Dave Campbell offers some tactics that pharma leaders can implement to stem the continued global threat of counterfeit drugs.

April 30, 2015.

Perrigo rejected Mylan’s second proposal for an acquisition valued at more than $34 billion, saying that the offer was too low to consider.

Takeda Pharmaceutical agrees to pay $2.4 billion to settle lawsuits from patients and family members who said the diabetes drug Actos caused bladder cancer.

FDA releases long-awaited guidance documents regarding the assessment of biosimilarity.

April 28, 2015.

April 28, 2015.

April 27, 2015.

April 27, 2015.

The industry continues to puzzle over FDA's proposed regulation of mobile medical apps (MMAs), writes Jill Wechsler.

April 24, 2015.

April 24, 2015.

April 23, 2015.

Teva announces that it would pay up to $40 billion in cash and stock to acquire Mylan.

The European Medicines Agency releases findings from marketing authorization application analysis.

April 21, 2015.

The agency has released draft guidance on providing regulatory submissions in regards to promotional labeling and advertising materials.

At the request of FDA, US Marshals seize unapproved prescription drugs from Florida distributor.

WHO says that results from clinical trials should be reported within 12 months of completion of the study

FDA extends ANDA rule comment period to June 8, 2015 after requests for more time.

April 16, 2015.

April 16, 2015.